The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis.
BACKGROUND
There has been no study comparing the long-term effects of ketotifen, oxatomide, and cetirizine for the treatment of perennial allergic rhinitis among children.


OBJECTIVE
We conducted a study to compare the efficacy of the three agents for the treatment of perennial allergic rhinitis among children.


METHODS
The study consisted of a double-blind, placebo-controlled, randomized design, comprising 69 perennial allergic rhinitis patients with mite allergy, aged 6 to 12 years, randomly assigned to 1 of 4 test treatment groups for 3 months: 19 in the cetirizine group (10 mg daily), 18 in the ketotifen group (1 mg, twice daily), 16 in the oxatomide group (1 mg/kg, twice daily), and 16 in the placebo group. We used the nasal symptom score of diary card and the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire and eosinophil cation protein peripheral blood total eosinophil count and immunoglobulin E level, eosinophil proportion from a nasal smear, and nasal peak expiratory flow rate to evaluate the effect of the four agents.


RESULTS
Cetirizine was significantly more effective at reducing the mean rhinorrhea score compared with oxatomide for both weeks 8 and 12 (P < 0.01). Before the end of week 12, cetirizine was significantly more effective than ketotifen (P < 0.01). Cetirizine and oxatomide significantly decreased the mean Pediatric Rhinoconjunctivitis Quality of Life Questionnaire score compared with the placebo for week 12 (P < 0.05).


CONCLUSIONS
Cetirizine was more effective than oxatomide and ketotifen for the relief of nasal congestion and rhinorrhea, and was responsible for significantly decreasing the eosinophil representation of a posttreatment nasal smear.
Lai
Dong-Shang
DS
Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC.
Lue
Ko-Huang
KH
Hsieh
Jie-Cheng
JC
Lin
Ker-Liang
KL
Lee
Hong-Sen
HS
D000485:Allergens / Q000009:adverse effects; D000818:Animals; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001798:Blood Proteins / Q000032:analysis; D017332:Cetirizine / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003233:Conjunctivitis, Allergic / Q000188:drug therapy; D004311:Double-Blind Method; D047091:Eosinophil Granule Proteins; D004802:Eosinophilia / Q000209:etiology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007665:Ketotifen / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009297:Nasal Mucosa / Q000473:pathology; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D039981:Pyroglyphidae / Q000276:immunology; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D012260:Ribonucleases; D012449:Safety; D012912:Sneezing; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000485:Allergens; D018926:Anti-Allergic Agents; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D010879:Piperazines; D007073:Immunoglobulin E; D012260:Ribonucleases; C015408:oxatomide; D007665:Ketotifen; D017332:Cetirizine